Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 10/20 | 0.60 |
| ▸ | MAPK3 | P27361 | 7/20 | 0.51 |
| ▸ | ITK | Q08881 | 2/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.43 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.42 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.42 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.42 |
| ▸ | TTK | P33981 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22044531 | 0.94 | MAPK1 (0.55) | MAPK1MAPK3ITKMAPK8MAPK10 | |
| SCHEMBL22044844 | 0.89 | ITK (0.48) | MAPK1MAPK3ITKMAPK8MAP2K4 | |
| SCHEMBL22044104 | 0.88 | ITK (0.49) | MAPK1MAPK3ITKMAPK8TTK | |
| SCHEMBL22044451 | 0.88 | ITK (0.53) | MAPK1MAPK3ITKMAPK8TTK | |
| SCHEMBL22044040 | 0.87 | ITK (0.62) | MAPK1MAPK3ITKMAPK8MAP2K4 | |
| SCHEMBL22043983 | 0.83 | MAPK1 (0.49) | MAPK1MAPK3 | |
| SCHEMBL22043984 | 0.83 | ITK (0.53) | MAPK1MAPK3ITKMAPK8TTK | |
| SCHEMBL22043979 | 0.83 | MAPK1 (0.51) | MAPK1MAPK3MAP2K4TTK | |
| SCHEMBL22044051 | 0.81 | MLYCD (0.51) | MAPK1MAPK3ITKMAPK8MAPK10 | |
| SCHEMBL22044456 | 0.80 | MAPK1 (0.61) | MAPK1MAPK3ITKMAPK8KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200172521-A1 | Five-Membered-Fused-Six-Membered Aza-Aromatic Ring Compound, Preparation Method Thereof, Pharmaceutical Composition And Application Thereof | Amcure Biosciences Pte. Ltd. (SG) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172521-A1 | Five-Membered-Fused-Six-Membered Aza-Aromatic Ring Compound, Preparation Method Thereof, Pharmaceutical Composition And Application Thereof | KRAS, NRAS, RASSF5 | MAPK1 3146/4885MAPK3 1726/4885ITK 2603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.